Valeritas is a Contributing Supporter of the Interactive Insulin Workshop at MEDS East Summit

BRIDGEWATER, N.J., Oct. 11, 2018 — Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced they are supporting interactive insulin workshops at the Metabolic & Endocrine Disease Summit (MEDS) in Orlando, Florida. This summit runs from October 10-13, 2018.

This four-day summit is the second of two semiannual conferences designed to advance the education of nurse practitioners and physician assistants who treat people with metabolic and endocrine diseases. As with the MEDS Summit that took place in April in San Diego, Valeritas is helping to support the 3.5-hour interactive Insulin Workshop. During this workshop, attendees are given an opportunity to broaden their understanding of, and to renew their confidence in managing patients on various insulin regimens, as well as to participate in interactive learning on the use of various insulin delivery options.

“We are happy to support continued education for practitioners who are focused on improving the health of people with diabetes,” said John Timberlake, President and Chief Executive Officer of Valeritas. “We believe simplifying insulin delivery is an important element to improving patient care and outcomes and are pleased that this workshop will educate nurse practitioners and physician assistants on advancements in insulin delivery.”

About Valeritas Holdings, Inc. Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, affordable, all-in-one basal-bolus insulin delivery option for patients with type 2 diabetes that is worn like a patch and can eliminate the need for taking multiple daily shots.  V-Go administers a continuous preset basal rate of insulin over 24 hours and it provides discreet on-demand bolus dosing at mealtimes.  It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.

More information is available at and our Twitter feed @Valeritas_US,


Subscribe to the Global Banking & Finance Review Newsletter for FREE
Get Access to Exclusive Reports to Save Time & Money

By using this form you agree with the storage and handling of your data by this website. We Will Not Spam, Rent, or Sell Your Information.
All emails include an unsubscribe link. You may opt-out at any time. See our privacy policy.

Forward-Looking Statements

This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.  Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at

Investor Contacts: Lynn Lewis or Greg Chodaczek Gilmartin Group 646-924-1769 [email protected]

Media Contact: Kevin Knight Knight Marketing Communications, Ltd. (206) 451-4823 [email protected]

Primary Logo